Corporate Activity
×
What happened?
Oobli, a sweet protein manufacturer, has received a “no questions” letter from the US Food and Drug Administration (FDA) for its monellin sweet protein, confirming its safety for use in food and beverages. This follows a similar clearance for brazzein, further strengthening its regulatory positioning.
Oobli is actively partnering with industry leaders like Grupo Bimbo to integrate sweet proteins into formulations, with the potential to replace up to 70% of sugar without compromising taste
Why It Matters.
| This milestone signals growing regulatory and industry acceptance of sweet proteins as viable sugar alternatives. Unlike traditional sweeteners, monellin and brazzein do not impact blood sugar levels, appealing health-conscious consumers and brands looking to reduce sugar. The FDA clearance enhances Oobli’s market credibility and accelerates adoption across the food and beverage industry | “The beauty of sweet proteins is that they take out almost 90% of sugar without you feeling like you have to make a taste tradeoff.” – Ali Wing, CEO of Oobli. |
What might come next.
- Increased R&D investment in sweet protein technology, potentially driving further industry innovation
- Expanded partnerships with F&B manufacturers, accelerating commercialization across multiple product categories
- Rising competitive activity as other players explore sweet protein alternatives in response to growing market demand
Need a thought partner?
Share your focus area or question to engage with our Analysts through the Business Objectives service.
Submit My Business ObjectiveOur Clients
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.
- © 2021 Cheers Interactive (India) Private Limited. All rights reserved. FutureBridge ® is a registered trademark of Cheers Interactive (India) Private Limited.
